578 related articles for article (PubMed ID: 22918778)
21. Intraarterial Peptide Receptor Radionuclide Therapy Using
Lawhn-Heath C; Fidelman N; Chee B; Jivan S; Armstrong E; Zhang L; Lindsay S; Bergsland EK; Hope TA
J Nucl Med; 2021 Feb; 62(2):221-227. PubMed ID: 32513903
[TBL] [Abstract][Full Text] [Related]
22. Additional information gained by positron emission tomography with (68)Ga-DOTATOC for suspected unknown primary or recurrent neuroendocrine tumors.
Nakamoto Y; Sano K; Ishimori T; Ueda M; Temma T; Saji H; Togashi K
Ann Nucl Med; 2015 Jul; 29(6):512-8. PubMed ID: 25894056
[TBL] [Abstract][Full Text] [Related]
23. Potential for Increasing Uptake of Radiolabeled
Pollard JH; Menda Y; Zamba KD; Madsen M; O'Dorisio MS; O'Dorisio T; Bushnell D
Cancer Biother Radiopharm; 2021 Oct; 36(8):632-641. PubMed ID: 34252288
[No Abstract] [Full Text] [Related]
24. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
[TBL] [Abstract][Full Text] [Related]
25. Is there a correlation between peptide receptor radionuclide therapy-associated hematological toxicity and spleen dose?
Kulkarni HR; Prasad V; Schuchardt C; Baum RP
Recent Results Cancer Res; 2013; 194():561-6. PubMed ID: 22918783
[TBL] [Abstract][Full Text] [Related]
26. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
[TBL] [Abstract][Full Text] [Related]
27. Sensitivity Comparison of
Nicolas GP; Schreiter N; Kaul F; Uiters J; Bouterfa H; Kaufmann J; Erlanger TE; Cathomas R; Christ E; Fani M; Wild D
J Nucl Med; 2018 Jun; 59(6):915-921. PubMed ID: 29191855
[TBL] [Abstract][Full Text] [Related]
28. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
[TBL] [Abstract][Full Text] [Related]
29. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.
Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
J Nucl Med; 2011 Dec; 52(12):1864-70. PubMed ID: 22072704
[TBL] [Abstract][Full Text] [Related]
30. ²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience.
Kratochwil C; Giesel FL; Bruchertseifer F; Mier W; Apostolidis C; Boll R; Murphy K; Haberkorn U; Morgenstern A
Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2106-19. PubMed ID: 25070685
[TBL] [Abstract][Full Text] [Related]
31. Contrast-enhanced ultrasound monitoring of perfusion changes in hepatic neuroendocrine metastases after systemic versus selective arterial 177Lu/90Y-DOTATOC and 213Bi-DOTATOC radiopeptide therapy.
Giesel FL; Wulfert S; Zechmann CM; Haberkorn U; Kratochwil C; Flechsig P; Kuder T; Schwartz LH; Bruchertseifer F
Exp Oncol; 2013 Jun; 35(2):122-6. PubMed ID: 23828389
[TBL] [Abstract][Full Text] [Related]
32. Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT.
Kulkarni HR; Baum RP
PET Clin; 2014 Jan; 9(1):83-90. PubMed ID: 25029937
[TBL] [Abstract][Full Text] [Related]
33. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of
Sawicki LM; Deuschl C; Beiderwellen K; Ruhlmann V; Poeppel TD; Heusch P; Lahner H; Führer D; Bockisch A; Herrmann K; Forsting M; Antoch G; Umutlu L
Eur Radiol; 2017 Oct; 27(10):4091-4099. PubMed ID: 28439648
[TBL] [Abstract][Full Text] [Related]
35. Successful Intra-arterial Peptide Receptor Radionuclide Therapy of DOTATOC-Negative High-Grade Liver Metastases of a Pancreatic Neuroendocrine Neoplasm Using 177Lu-DOTA-LM3: A Somatostatin Receptor Antagonist.
Zhang J; Kulkarni HR; Singh A; Baum RP
Clin Nucl Med; 2020 Mar; 45(3):e165-e168. PubMed ID: 31977464
[TBL] [Abstract][Full Text] [Related]
36. Qualitative and quantitative image analysis of CT and MR imaging in patients with neuroendocrine liver metastases in comparison to (68)Ga-DOTATOC PET.
Flechsig P; Zechmann CM; Schreiweis J; Kratochwil C; Rath D; Schwartz LH; Schlemmer HP; Kauczor HU; Haberkorn U; Giesel FL
Eur J Radiol; 2015 Aug; 84(8):1593-1600. PubMed ID: 25999064
[TBL] [Abstract][Full Text] [Related]
37. 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT.
Kroiss A; Putzer D; Decristoforo C; Uprimny C; Warwitz B; Nilica B; Gabriel M; Kendler D; Waitz D; Widmann G; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2013 Apr; 40(4):514-23. PubMed ID: 23291643
[TBL] [Abstract][Full Text] [Related]
38. Peptide receptor radionuclide therapy of Merkel cell carcinoma using (177)lutetium-labeled somatostatin analogs in combination with radiosensitizing chemotherapy: a potential novel treatment based on molecular pathology.
Salavati A; Prasad V; Schneider CP; Herbst R; Baum RP
Ann Nucl Med; 2012 May; 26(4):365-9. PubMed ID: 22361935
[TBL] [Abstract][Full Text] [Related]
39. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results.
Beiderwellen KJ; Poeppel TD; Hartung-Knemeyer V; Buchbender C; Kuehl H; Bockisch A; Lauenstein TC
Invest Radiol; 2013 May; 48(5):273-9. PubMed ID: 23493121
[TBL] [Abstract][Full Text] [Related]
40. Polish experience in Peptide receptor radionuclide therapy.
Kunikowska J; Królicki L; Sowa-Staszczak A; Hubalewska-Dydejczyk A; Pawlak D; Mikolajczak R; Handkiewicz-Junak D; Szaluś N; Kamiński G; Cwikla J; Jakuciński M; Lukiewicz A; Kowalska A; Gut P
Recent Results Cancer Res; 2013; 194():467-78. PubMed ID: 22918776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
